(Q38137027)

English

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis

scientific article published on January 2014

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

0 references

The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1 reference

based on heuristic

inferred from title

type 2 diabetes

1 reference

based on heuristic

inferred from title

systematic review

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

J E Schopman

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

A C R Simon

2

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

S J M Hoefnagel

3

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

J B L Hoekstra

4

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

R J P M Scholten

5

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

F Holleman

6

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 January 2014

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Diabetes - Metabolism: Research and Reviews

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

11-22

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Exenatide versus glibenclamide in patients with diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and tolerability of vildagliptin as an add-on to glimepiride in Japanese patients with Type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Vildagliptin add-on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2-year study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Liraglutide provides similar glycaemic control as glimepiride (both in combination with metformin) and reduces body weight and systolic blood pressure in Asian population with type 2 diabetes from China, South Korea and India: a 16-week, randomized,

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Linagliptin (BI 1356), a potent and selective DPP-4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Basal insulin and cardiovascular and other outcomes in dysglycemia

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use.

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Comparison of efficacy, secondary failure rate, and complications of sulfonylureas

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

21 January 2018

Prospective and retrospective recording of severe hypoglycaemia, and assessment of hypoglycaemia awareness in insulin-treated Type 2 diabetes

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

7 January 2021

based on heuristic

inferred from DOI database lookup

Symptomatic Hypoglycaemia in 411 Type 1 Diabetic Patients

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

7 January 2021

based on heuristic

inferred from DOI database lookup

2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

7 January 2021

based on heuristic

inferred from DOI database lookup

Glibenclamide vs gliclazide in type 2 diabetes of the elderly

1 reference

https://api.crossref.org/works/10.1002%2FDMRR.2470

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/DMRR.2470

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38137027&oldid=2171636679"